Navigation Links
Structure for Success: Leadership Development Programs at Pharmaceutical Companies
Date:3/11/2008

CHAPEL HILL, N.C., March 11 /PRNewswire/ -- When training sales managers, companies tend to focus on change management and influencing employees as key areas for skills development. The added stress on change management may be associated with the focus of large companies on sales associate turnover, according to research by Best Practices, LLC, a leading pharmaceutical research firm.

Download a complimentary sample of this research, "Sales Management Leadership Development Programs: Structuring for Success," at http://www3.best-in-class.com/br117.htm.

The analysis identifies the different structures, administration techniques and strategies for leadership development programs. In addition, the client-driven study defines content of the program and its delivery, as well as performance management for the period after the program. Specific topics include:

-- Program Structure

-- Administration/Sponsorship

-- Program Content

-- Time Allocation per Content Area

-- Delivery Formats of Content Areas

-- Performance Management

"Sales Management Leadership Development Programs: Structuring for Success" reflects the type of research Best Practices, LLC conducts for members of its Business Excellence Board (http://www3.best-in-class.com/beb), a research and advisory service for health care and pharmaceutical executives.

For information on other services by Best Practices, LLC and its Business Excellence Board, contact Cameron Tew at ctew@best-in-class.com or 919-403-0251, ext. 246.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.
'/>"/>

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. LifeMasters Strengthens Capital Structure with $15 Million in Funding from Existing Investors
2. Measurement technique probes surface structure of gold nanocrystals
3. University of Pittsburgh researchers crack code of 3-D structure in key metabolic protein
4. Scientists determine structure of brain receptor implicated in epilepsy and PMT
5. New technique takes a big step in examination of small structures
6. Titanium Group Implements Biometric Sign-On Infrastructures for Hong Kong Immigration Department
7. Brad Williams Joins OrthoSynetics(TM) as Director, IT Infrastructure
8. Norton Healthcare Delivers Information to the Point-of-Care with EMC Information Infrastructure
9. The structure of resistance
10. U of M researchers determine structure of protein that mutates DNA of the AIDS virus HIV-1
11. Enzyme structure reveals new drug targets for cancer and other diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2Merieux Alliance Becomes Institut Merieux 2Merieux Alliance Becomes Institut Merieux 3Merieux Alliance Becomes Institut Merieux 4Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 1Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 2Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 3Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 4Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 5Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 6Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 7TCT 2009 to Feature vProtect 28TM 29 Luminal Shield a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical 14134 1TCT 2009 to Feature vProtect 28TM 29 Luminal Shield a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical 14134 2Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 1Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 2Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 3Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 4Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 5Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 6Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 7